Cambridge Technologies announces Mark Weaver has assumed the role of CEO. Weaver was previously CEO of Newsham Choice Genetics, then a private consultant and partner in WW Research.

Randy Simonson, also a Regent for the University of Minnesota, will continue to be an integral team member with Cambridge as its chief strategy officer.

Cambridge Technologies provides the latest in diagnostic and manufacturing techniques and utilizes Precision Vaccinology to provide autogenous vaccine solutions for swine and bovine veterinarians.

Source: Cambridge Technologies, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.